Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurocrine Adds Epilepsy Assets From Xenon

Xenon will have freedom to focus on later-stage pipeline

Executive Summary

Neurocrine plans to advance XEN901 into Phase II in a rare pediatric epilepsy indication while eyeing opportunity in adult focal epilepsy. Xenon increases its runway to develop a pair of mid-stage epilepsy drugs.

You may also be interested in...



Deal Watch: AstraZeneca Continues Divestments By Offloading US/Canada Seroquel Rights

Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.

Neurocrine Shines In Congenital Adrenal Hyperplasia, But Competitor Is Close

Spruce's competing drug with same mechanism of action is also in Phase II, with data expected at the end of March.

Voyager Nabs Neurocrine As Partner In CNS Gene Therapy

Voyager signals Phase II study of gene therapy VY-AADC in Parkinson's disease is on track, with no expectations for regulatory setbacks.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141275

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel